Gastrointestinal Stromal Tumor (GIST)


Hagit Baris-Feldman

Israel Emerges as Global Powerhouse in Rare Disease Research

TEL AVIV, Israel — On the 6th floor of Schneider Children’s Hospital in the Tel Aviv suburb of Petah Tikva, 30 children with Alagille syndrome and 2 with lysosomal acid lipase deficiency (LAL-D) receive specialized treatment from a trio of pediatric hepatologists. Across town, at Sheba Medical Center’s Edmond and Lily Safra Children’s Hospital, pediatric…
NORD t-shirts for sale

NORD Recognizes Progress in Fight Against Rare Disease With 2021 Rare Impact Awards

Under COVID-19’s lingering shadow, the National Organization of Rare Disorders (NORD) has presented its 2021 Rare Impact Awards to 24 pharmaceutical firms, researchers, politicians, and nonprofit groups for their efforts over the past year on behalf of patients with such illnesses. The virtual ceremony was hosted by John Whyte, MD, MPH, chief medical officer at WebMD, with commentary…

Patient Perspectives

GIST Clinical Insights

IPF experimental therapies

Predicting Prognosis in Patients With GIST

Much scientific research in recent years has centered on uncovering prognostic indicators for malignant diseases. The main goal of treatment is always curative, but in cases in which that is currently impossible, the physician’s attention then turns toward extending and improving the quality of life of patients.  Gastrointestinal stromal tumors (GIST) are cancers that can…

Rare Care Podcast

Advocating for People With Gastrointestinal Stromal Tumor: An interview with Peter Knox, senior research director at the Life Raft Group